Management ChangeJun 23, 2026, 07:01 AM
Avalo Therapeutics Appoints Ron Philip to Board of Directors
AI Summary
Avalo Therapeutics, Inc. announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings over 30 years of biopharmaceutical leadership, including significant commercial and strategic execution experience, having guided multiple companies through product launches and billion-dollar exits. His expertise is expected to be invaluable as Avalo advances abdakibart, following positive Phase 2 results, into Phase 3 for hidradenitis suppurativa (HS).
Key Highlights
- Ron Philip appointed to Avalo Therapeutics' Board of Directors.
- Mr. Philip brings over 30 years of biopharmaceutical leadership experience.
- He previously served as CEO of Orbital Therapeutics, acquired for $1.5 billion by Bristol Myers Squibb.
- He also served as CEO of Spark Therapeutics, acquired for $4.8 billion by Roche.
- Mr. Philip led the commercial launch of LUXTURNA®, Spark's first FDA-approved gene therapy.
- His expertise will be crucial for advancing abdakibart into Phase 3 for hidradenitis suppurativa (HS).
- Avalo recently reported positive Phase 2 LOTUS topline results for abdakibart in HS.
Price Impact
More from AVTX